JPRN-jRCT1030210695招募中未知
Hyperkalemia registryAn observational prospective cohort study for long-term management of hyperkalemia in patients with chronic kidney disease or heart failure - HK registry main
Morita Naru0 个研究点目标入组 350 人开始时间: 2022年3月26日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 350
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •a) Aged >=20 years
- •b) Patients with hyperkalemia who meet the following criteria
- •i) Being treated with potassium binders for hyperkalemia at the time of enrolment,and having started receiving potassium binders within 6 months before enrolment
- •c) Having been diagnosed as CKD(>=stage 3b) or HF diagnosed by investigators,and as defined below
- •c-1) CKD is diagnosed based on the CKD guidelines issued by the Japanese Society of Nephrologyxxv as being either or both of condition 1 and 2 for >=3 months
- •i) Clear signs of kidney impairment based on the results of urinalysis,imaging,blood test,or biopsy.Presence of proteinuria,especially more than 0.15g/gCr(albuminuria more than 30mg/gCr).
- •ii) GFR <45 mL/min/1.73m2
- •In routine clinical practice,GFR is estimated using serum creatinine,gender,and age,according to the following equation.
- •eGFR creat (mL/min/1.73m2) = 194 x serum creatinine (mg/dL)-1.094 x age (years)-0.287 (for female patients, x 0.739)
- •Stage 3b of CKD,or higher,defined based on the following eGFR categories
- •i) Stage 3b 30 mL/min/1.73m2 less than or equal to eGFR <45 mL/min/1.73m2
- •ii) Stage 4 15 mL/min/1.73m2 less than or equal to eGFR <30 mL/min/1.73m2
- •iii) Stage 5 eGFR <15 mL/min/1.73m2
- •c-2) Patients with HFwill be enrolled if patients meet following criteria
- •i) NYHA class II-IV,within 6 months
- •ii) Patients with a diagnosis or history of heart failure,hospitalization,and laboratory records of any of the following
- •NT-proBNP>=400 pg/ml or BNP>=100 pg/ml,or pathological findings such as abnormal cardiac function by UCG/CT/MRI/catheterization/nuclear medicine examination
- •d) Provision of signed,written,and detailed informed consent
排除标准
- •a) Currently on any chronic RRT(including hemodialysis or peritoneal dialysis >30 days,or kidney transplant)within 6 months before enrolment
- •b) Patients with acute kidney injury(AKI)* within 6 months before enrolment
- •c) Patients with acute heart failure within 3 months before enrolment
- •d) Patients who received blood transfusion within 6 months before enrolment
- •e) Patients with active malignancy or whose life expectancy is less than 6 months
- •f) GI disturbance,chronic diarrhoea,or GI stoma if,as judged by the investigators,that condition or its treatment has an important impact on S-K values
- •g) Autoimmune disease if,as judged by the investigators,that condition or its treatment has an important impact on S-K values
- •h) Patients who are suspected,on the basis of laboratory data,to have pseudohyperkalemia(abnormality in the sample,a history of severe leukocytopenia or thrombocytopenia)
- •i) Patients with recent traumatic injury
- •j) Patients who are pregnant,lactating,or planning to become pregnant
- •k) Current participation in a clinical trials,i.e.an interventional studies
- •l) Presence of a condition that,in the opinion of the investigator,
- •i) would places the subject at undue risk,or
- •ii) would potentially jeopardizes the quality of the data to be generated,or
- •iii) would prevent the patient from performing protocol-defined tasks for physical or mental reasons,or
- •iv) would prevent the patient from understanding the contents of the self-administered questionnaire and responding to its questions on his/her own,or
- •v) would,for some other reason,make the patient inappropriate for this study.
- •* AKI is diagnosed if at least one of the following three conditions is met.Note:This follows KDIGO clinical guidelines.
- •1.Delta sCr >= 0.3 mg/dL(within 48 hours)
- •2.1.5 x increase from the baseline value of sCr(within 7 days)
- •3.Urine volume 0.5 mL/kg/hr or less,lasting more than 6 hours
研究者
相似试验
已完成
不适用
An Observational Prospective Cohort Study for Long-term Management of Hyperkalemia in Patients With Chronic Kidney Disease or Heart FailureHyperkalemiaNCT05297409AstraZeneca352
已完成
不适用
Tracking Treatment Pathways in Adult Patients With Hyperkalemia.HyperkalemiaNCT05408039AstraZeneca1,331
Unknown
不适用
Retrospective Survey of Hyperkalemia in HemodialysisHemodialysis ComplicationNCT05020717Peking University People's Hospital300
已完成
不适用
Prevalence and Risk Factors of Hyperkalemia among Advanced Chronic Kidney Disease Patients in Chanthaburi province, Thailand : A Cross sectional StudyHyperkalemia in advanced CKD patientsHyperkalemia, Renal insufficiency, geographic factorTCTR20240401002Prapokklao Medical Education Center171
已完成
不适用
A study to determine the incidence of hypercalcemia with calcipotriol hydrate/betamethasone dipropionate ester fixed dose combination product in patients with severe psoriasis vulgarisSevere psoriasis vulgarisJPRN-UMIN000020325Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences25